The cancer immunotherapy drug Opdivo is reattempting reimbursement as a first-line treatment once more.

According to industry sources, Ono Pharma Korea and BMS Korea’s PD-1 inhibiting cancer immunotherapy Opdivo (nivolumab) will be deliberated by the Cancer Disease Deliberation Committee (CDDC) of the Health Insurance Review and Assessment Service on the 28th.

In Korea, Opdivo was approved ‘as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma’ in June last year. With the added indication, the drug became the first and only domestica